MedTrace Logo

FTIH of ECC4703 in Healthy Volunteers

NCT05552274 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2024-07-05

No results posted yet for this study

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL

Conditions

  • Non-alcoholic Steatohepatitis (NASH)

Interventions

DRUG

ECC4703

ECC4703 will be administered as 1 mg, 10 mg and 40 mg capsules. ECC4703 will be administered as oral capsules during each dosing day.

DRUG

Placebo

Matching Placebo will be administered as oral capsules. Matching Placebo will be given orally during each dosing day.

Sponsors & Collaborators

  • Eccogene

    lead INDUSTRY

Principal Investigators

  • Eccogene · Eccogene Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-16
Primary Completion
2023-10-26
Completion
2023-10-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05552274 on ClinicalTrials.gov